Key Events This Week
23 Mar: Valuation shifts to fair amid sector comparisons
27 Mar: Technical momentum shifts amid mixed market signals
27 Mar: Week closes at Rs.765.45 (+5.32%) outperforming Sensex
Valuation Shift on 23 March: A More Balanced Market View
On 23 March 2026, Windlas Biotech’s valuation was reassessed from attractive to fair, reflecting a recalibration amid sector-wide valuation pressures. The stock closed at Rs.733.40, up 0.91% on the day, while the Sensex fell sharply by 3.13%, closing at 32,377.87. This divergence highlighted the stock’s relative resilience.
The company’s price-to-earnings ratio stood at 23.13, with a price-to-book value of 2.89, positioning it moderately below many expensive peers such as Ajanta Pharma and J B Chemicals. Enterprise value multiples (EV/EBIT at 17.77 and EV/EBITDA at 12.51) further underscored a balanced valuation.
Windlas Biotech’s return on capital employed (ROCE) of 24.60% and return on equity (ROE) of 12.60% indicate efficient capital utilisation, though the dividend yield remains modest at 0.79%. Despite a recent downgrade to a Sell rating by MarketsMOJO, the stock’s long-term returns remain impressive, with a three-year gain of 204.58% compared to the Sensex’s 29.33%.
Turnaround taking shape! This Small Cap from NBFC sector just hit profitability with strong business fundamentals showing up. Catch it before the major breakout happens!
- - Recently turned profitable
- - Strong business fundamentals
- - Pre-breakout opportunity
Strong Price Rally on 24 and 25 March Amid Positive Market Sentiment
Following the valuation update, Windlas Biotech’s shares surged on 24 March, closing at Rs.762.65, a 3.99% gain on the day, outperforming the Sensex which rose 1.95%. The momentum continued on 25 March with a 2.28% increase to Rs.780.05, marking the week’s highest close. Trading volumes also increased notably, with 1,015 and 1,823 shares traded respectively, signalling growing investor interest.
This rally coincided with a broader market recovery, as the Sensex advanced by 1.95% and 1.93% on these days. Windlas Biotech’s outperformance during this period reflected renewed confidence, possibly driven by the fair valuation status and sector comparisons.
Technical Momentum Shifts on 27 March: Mixed Signals Amid Market Volatility
On 27 March, the stock retreated slightly, closing at Rs.765.45, down 1.87% from the previous close, while the Sensex declined 2.11%. Despite the dip, technical indicators showed a shift from a bearish to a mildly bearish outlook, suggesting tentative improvement in market sentiment.
Key momentum indicators presented a complex picture: the weekly MACD remained bearish, but the monthly MACD improved to mildly bearish. The Know Sure Thing (KST) indicator was mildly bullish on the weekly chart but mildly bearish monthly. The Relative Strength Index (RSI) was neutral, indicating consolidation rather than directional bias.
Daily moving averages stayed bearish, signalling short-term pressure, while On-Balance Volume (OBV) showed mildly bearish weekly trends but mildly bullish monthly trends, hinting at longer-term accumulation despite recent volatility.
Windlas Biotech’s technical momentum thus reflects a stock in transition, with cautious optimism tempered by lingering bearish pressures. The stock’s ability to sustain gains will depend on overcoming resistance levels indicated by moving averages and volatility bands.
Is Windlas Biotech Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Daily Price Performance vs Sensex: 23–27 March 2026
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-23 | Rs.733.40 | +0.91% | 32,377.87 | -3.13% |
| 2026-03-24 | Rs.762.65 | +3.99% | 33,009.57 | +1.95% |
| 2026-03-25 | Rs.780.05 | +2.28% | 33,645.89 | +1.93% |
| 2026-03-27 | Rs.765.45 | -1.87% | 32,935.19 | -2.11% |
Key Takeaways from the Week
Positive Signals: Windlas Biotech outperformed the Sensex by a significant margin, gaining 5.32% versus the index’s 1.46% decline. The valuation shift to fair reflects a more balanced market perception, supported by solid capital efficiency metrics such as a 24.60% ROCE. The technical momentum’s move from bearish to mildly bearish suggests stabilisation and potential for recovery.
Cautionary Notes: Despite short-term gains, the stock’s technical indicators remain mixed, with daily moving averages still bearish and momentum oscillators showing conflicting signals. The company’s Sell rating and Mojo Score of 40.0 underline ongoing risks. Additionally, the stock’s one-year performance remains weak relative to the Sensex, highlighting vulnerability to sector-specific headwinds.
Conclusion: A Week of Transition and Outperformance
Windlas Biotech Ltd’s performance during the week ending 27 March 2026 was marked by a notable outperformance against the broader market, driven by a recalibrated valuation and a subtle shift in technical momentum. While the stock’s fair valuation and efficient capital use provide a solid foundation, mixed technical signals and a cautious rating suggest that investors should monitor developments closely.
The stock’s ability to sustain gains will depend on overcoming short-term resistance and confirming a bullish technical trend. For now, Windlas Biotech remains a small-cap player navigating a competitive pharmaceutical sector with a complex interplay of optimism and caution.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
